Otsuka's Abilify MyCite, the first medication to embed Proteus's "body powered" sensors for medication adherence monitoring, received Food and Drug Administration (FDA) clearance. The drug choice of an antipsychotic for schizophrenia received media backlash due...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)